S M Stahl

Summary

Affiliation: Neuroscience Education Institute
Country: USA

Publications

  1. ncbi request reprint Neurotransmission of cognition, part 3. Mechanism of action of selective NRIs: both dopamine and norepinephrine increase in prefrontal cortex
    Stephen M Stahl
    Neuroscience Education Institute, Carlsbad, CA 92009, USA
    J Clin Psychiatry 64:230-1. 2003
  2. doi request reprint Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study
    Stephen M Stahl
    Department of Psychiatry, University of California, San Diego School of Medicine, San Diego, USA
    J Clin Psychiatry 74:507-15. 2013
  3. doi request reprint Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment
    Debbi A Morrissette
    Neuroscience Education Institute, Carlsbad, CA, USA
    CNS Spectr 17:10-21. 2012
  4. doi request reprint Psychotherapy as an epigenetic 'drug': psychiatric therapeutics target symptoms linked to malfunctioning brain circuits with psychotherapy as well as with drugs
    S M Stahl
    Department of Psychiatry, University of California San Diego, San Diego, CA, USA
    J Clin Pharm Ther 37:249-53. 2012
  5. ncbi request reprint A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation
    S M Stahl
    Neuroscience Education Institute, 5857 Owens Avenue Suite 102, Carlsbad, CA 92008, USA
    Curr Med Chem 11:313-27. 2004
  6. ncbi request reprint Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial
    Stephen M Stahl
    Neuroscience Education Institute, Carlsbad, CA, USA
    J Clin Psychiatry 64:1322-7. 2003
  7. ncbi request reprint Differences in mechanism of action between current and future antidepressants
    Stephen M Stahl
    Neuroscience Education Institute, Carlsbad, CA 92009, USA
    J Clin Psychiatry 64:13-7. 2003
  8. ncbi request reprint Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER
    Stephen M Stahl
    Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
    CNS Spectr 12:703-11. 2007
  9. ncbi request reprint High-cost use of second-generation antipsychotics under California's Medicaid program
    Stephen M Stahl
    Neuroscience Education Institute, 5857 Owens Avenue, Suite 102, Carlsbad, California 92008, USA
    Psychiatr Serv 57:127-9. 2006
  10. ncbi request reprint Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism
    Stephen M Stahl
    Department of Psychiatry, University of California, San Diego, CA, USA
    Int J Neuropsychopharmacol 10:575-8. 2007

Detail Information

Publications94

  1. ncbi request reprint Neurotransmission of cognition, part 3. Mechanism of action of selective NRIs: both dopamine and norepinephrine increase in prefrontal cortex
    Stephen M Stahl
    Neuroscience Education Institute, Carlsbad, CA 92009, USA
    J Clin Psychiatry 64:230-1. 2003
    ..Thus, blocking norepinephrine transporters leads to an increase in both dopamine and norepinephrine levels in prefrontal cortex as well as improvement in cognition in attention-deficit/hyperactivity disorder...
  2. doi request reprint Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study
    Stephen M Stahl
    Department of Psychiatry, University of California, San Diego School of Medicine, San Diego, USA
    J Clin Psychiatry 74:507-15. 2013
    ..Persistence of symptom improvement was assessed as a secondary outcome...
  3. doi request reprint Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment
    Debbi A Morrissette
    Neuroscience Education Institute, Carlsbad, CA, USA
    CNS Spectr 17:10-21. 2012
    ..We also discuss the utility of depot antipsychotic formulations for improving the chances of attaining long-term therapeutic results...
  4. doi request reprint Psychotherapy as an epigenetic 'drug': psychiatric therapeutics target symptoms linked to malfunctioning brain circuits with psychotherapy as well as with drugs
    S M Stahl
    Department of Psychiatry, University of California San Diego, San Diego, CA, USA
    J Clin Pharm Ther 37:249-53. 2012
    ..The leading notion of how therapeutic effects occur in psychiatric disorders is that they happen when symptoms are reduced by improving the efficiency of information processing in hypothetically malfunctioning brain circuits...
  5. ncbi request reprint A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation
    S M Stahl
    Neuroscience Education Institute, 5857 Owens Avenue Suite 102, Carlsbad, CA 92008, USA
    Curr Med Chem 11:313-27. 2004
    ..Existing evidence suggests that the best treatments for schizophrenia and psychosis may be long-term trials of a sequence of atypical antipsychotic monotherapies at therapeutic doses...
  6. ncbi request reprint Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial
    Stephen M Stahl
    Neuroscience Education Institute, Carlsbad, CA, USA
    J Clin Psychiatry 64:1322-7. 2003
    ..This study evaluated the safety and efficacy of escitalopram in outpatients diagnosed with panic disorder...
  7. ncbi request reprint Differences in mechanism of action between current and future antidepressants
    Stephen M Stahl
    Neuroscience Education Institute, Carlsbad, CA 92009, USA
    J Clin Psychiatry 64:13-7. 2003
    ..The introduction of antidepressants with novel mechanisms of action could potentially revolutionize the treatment of depression...
  8. ncbi request reprint Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER
    Stephen M Stahl
    Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
    CNS Spectr 12:703-11. 2007
    ..Generalized anxiety disorder (GAD) is a chronic illness with psychic and somatic symptoms that do not respond uniformly in the first weeks of treatment...
  9. ncbi request reprint High-cost use of second-generation antipsychotics under California's Medicaid program
    Stephen M Stahl
    Neuroscience Education Institute, 5857 Owens Avenue, Suite 102, Carlsbad, California 92008, USA
    Psychiatr Serv 57:127-9. 2006
    ..This study assessed patterns of antipsychotic use to identify uses that are associated with high economic cost but for which there is no documented efficacy...
  10. ncbi request reprint Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism
    Stephen M Stahl
    Department of Psychiatry, University of California, San Diego, CA, USA
    Int J Neuropsychopharmacol 10:575-8. 2007
  11. ncbi request reprint Negative symptoms of schizophrenia: a problem that will not go away
    S M Stahl
    Department of Psychiatry, University of California, San Diego, CA, USA
    Acta Psychiatr Scand 115:4-11. 2007
    ..Although efforts thus far to elucidate a distinct schizophrenia subtype based upon negative symptoms have yielded mixed results, there are nevertheless neurobiological correlates of the negative symptom typology...
  12. ncbi request reprint The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice
    Stephen M Stahl
    Department of Psychiatry, University of California San Diego, USA
    J Clin Psychiatry 64:6-12. 2003
    ..Efficacy and tolerability data from trials to date indicate that ziprasidone's clinical activity is consistent with its receptor profile...
  13. ncbi request reprint Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease
    Stephen M Stahl
    Department of Psychiatry, University of California at San Diego and Neuroscience Education Institute, San Diego, CA 92008, USA
    Curr Med Res Opin 20:517-24. 2004
    ..This study examined whether galantamine, an AChEI with nicotinic modulation, is associated with nighttime sleeprelated problems...
  14. ncbi request reprint Understanding pain in depression
    Stephen Stahl
    Neuroscience Education Institute, Carlsbad, CA 92009, USA
    Hum Psychopharmacol 19:S9-S13. 2004
    ..A dysfunction at the level of the serotonergic and noradrenergic neurons can thus affect both the ascending and descending pathways resulting in the psychological and somatic symptoms of depression but also in physical painful symptoms...
  15. doi request reprint Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    S M Stahl
    Department of Psychiatry, University of California, San Diego School of Medicine, San Diego, CA 92008, USA
    Acta Psychiatr Scand 119:171-9. 2009
    ....
  16. doi request reprint Fibromyalgia--pathways and neurotransmitters
    Stephen M Stahl
    Department of Psychiatry, University of California, San Diego, CA, USA
    Hum Psychopharmacol 24:S11-7. 2009
    ....
  17. doi request reprint Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies
    S Stahl
    Department of Psychiatry, UCSD, San Diego, CA 92008, USA
    J Affect Disord 122:39-45. 2010
    ..Dysphoric mania is a common and often difficult to treat subset of bipolar mania that is associated with significant depressive symptoms...
  18. doi request reprint Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial
    Stephen M Stahl
    1930 Palomar Point Way, Ste 103, Carlsbad, CA 92008, USA
    J Clin Psychiatry 71:616-26. 2010
    ..To evaluate the efficacy, safety, and tolerability of fixed-dose agomelatine 25 and 50 mg/d in the treatment of outpatients with moderate-to-severe major depressive disorder (MDD) compared to placebo...
  19. ncbi request reprint Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence?
    Stephen M Stahl
    Neuroscience Education Institute, and Department of Psychiatry, University of California, San Diego, CA 92008, USA
    Int J Neuropsychopharmacol 7:113-6. 2004
  20. doi request reprint A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial
    Stephen M Stahl
    Department of Psychiatry, University of California, San Diego, CA 92093 9116 A, USA
    J Clin Psychopharmacol 30:425-30. 2010
    ....
  21. pmc Finding what you are not looking for: strategies for developing novel treatments in psychiatry
    Stephen M Stahl
    Department of Psychiatry, University of California San Diego, San Diego, California 92037, USA
    NeuroRx 3:3-9. 2006
    ..In many cases, the new indications are the more important therapeutic contributions and the most successful commercial application of a drug. Here we describe this strategy of psychiatric drug development and provide numerous examples...
  22. ncbi request reprint Evidence of early onset of antidepressant effect in randomized controlled trials
    S M Stahl
    Clinical Neuroscience Research Center, San Diego, Calif 92122, USA
    J Clin Psychiatry 62:17-23; discussion 37-40. 2001
    ....
  23. ncbi request reprint Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition
    Stephen M Stahl
    Neuroscience Education Institute, Carlsbad, Calif 92009, USA
    J Clin Psychiatry 64:110-1. 2003
    ..Selective norepinephrine reuptake inhibitors such as atomoxetine increase both dopamine and norepinephrine in frontal cortex and may thereby enhance cognitive functioning in attention-deficit/hyperactivity disorder...
  24. ncbi request reprint Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression
    Stephen M Stahl
    The Neuroscience Education Institute, Carlsbad, California 92009, USA
    Biol Psychiatry 52:1166-74. 2002
    ..The dual serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine is a dual reuptake inhibitor that may therefore offer greater efficacy than selective serotonin reuptake inhibitors (SSRIs)...
  25. ncbi request reprint The 5-HT1A agonist ipsapirone enhances EEG slow wave activity in human sleep and produces a power spectrum similar to 5-HT2 blockade
    E Seifritz
    Department of Psychiatry, UCSD, USA
    Neurosci Lett 209:41-4. 1996
    ..The spectral non-REM sleep EEG profile might be used to investigate central 5-HT function in humans...
  26. doi request reprint The metabolic syndrome and schizophrenia
    J M Meyer
    Veterans Affairs San Diego Healthcare System, La Jolla, CA, USA
    Acta Psychiatr Scand 119:4-14. 2009
    ....
  27. ncbi request reprint Does depression hurt?
    Stephen M Stahl
    Neuroscience Education Institute in Carlsbad, CA 92009, USA
    J Clin Psychiatry 63:273-4. 2002
    ..Despite these results, the best treatment of depression currently recognizes the 3 types of symptoms and targets them all for complete remission no matter which drug is used...
  28. doi request reprint Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia
    Dennis H Kim
    Arbor Scientia, Carlsbad, California 92008, USA
    Neurotherapeutics 6:78-85. 2009
    ..In this article we present a discussion of some of the receptor targets that are currently thought to mediate symptoms of schizophrenia, as well as their possible implications for the design of future multifunctional antipsychotics...
  29. ncbi request reprint Risperidone and paroxetine given singly and in combination for bipolar depression
    Richard C Shelton
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37212, USA
    J Clin Psychiatry 65:1715-9. 2004
    ..The current study was intended to evaluate the effects of the novel antipsychotic risperidone, the selective serotonin reup-take inhibitor (SSRI) paroxetine, and the combination in patients with bipolar disorder...
  30. ncbi request reprint Atypical antipsychotics: matching receptor profile to individual patient's clinical profile
    Darius K Shayegan
    Neuroscience Education Institute, Carlsbad, CA 92008, USA
    CNS Spectr 9:6-14. 2004
    ..However, no two atypical antipsychotics possess the same portfolio of actions upon all of these additional neurotransmitter systems...
  31. ncbi request reprint Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels
    Stephen M Stahl
    Neuroscience Education Institute, Carlsbad, CA 92009, USA
    J Clin Psychiatry 65:738-9. 2004
    ..Actions of certain anticonvulsants upon voltage-gated sodium channels may not only explain why they are effective mood stabilizers but may also explain why they could be useful adjuncts to antipsychotics for resistant psychosis...
  32. ncbi request reprint Emotion processing, the amygdala, and outcome in schizophrenia
    Darius K Shayegan
    Department of Clinical Research, Neuroscience Education Institute, 5857 Owens Ave, Suite 102, Carlsbad, CA 92008, USA
    Prog Neuropsychopharmacol Biol Psychiatry 29:840-5. 2005
    ..Here, we review deficits in the processing of emotion in schizophrenia, the role of the amygdala in the context of these deficits, and the functional implications of this relationship upon patient outcome...
  33. ncbi request reprint Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent
    Stephen M Stahl
    Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
    CNS Spectr 12:739-44. 2007
  34. ncbi request reprint SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants
    Stephen M Stahl
    Department of Psychiatry, University of California, San Diego, San Diego, CA, USA
    CNS Spectr 10:732-47. 2005
    ..Duloxetine and milnacipran appear better tolerated and essentially devoid of cardiovascular toxicity...
  35. ncbi request reprint L-methylfolate: a vitamin for your monoamines
    Stephen M Stahl
    Neuroscience Education Institute, 1930 Palomar Point Way, Ste 101, Carlsbad, CA 92009, USA
    J Clin Psychiatry 69:1352-3. 2008
    ..Synthesis of the monoamine neurotransmitters serotonin, dopamine, and norepinephrine is regulated by L-methylfolate, a derivate of the vitamin folate...
  36. ncbi request reprint Symptoms and circuits, part 3: schizophrenia
    Stephen M Stahl
    Neuroscience Education Institute in Carlsbad, CA 92009, USA
    J Clin Psychiatry 65:8-9. 2004
    ..Schizophrenia is composed of not only positive symptoms, but also cognitive and affective symptoms that contribute significantly to morbidity. Each of these symptoms may be mediated by a separate and distinct neuronal circuit...
  37. ncbi request reprint Awakening to the psychopharmacology of sleep and arousal: novel neurotransmitters and wake-promoting drugs
    Stephen M Stahl
    Neuroscience Education Institute, Carlsbad, Calif 92009, USA
    J Clin Psychiatry 63:467-8. 2002
    ..Selectively inducing normal wakefulness without stimulating external vigilance may lead to therapeutic benefits not only in sleep disorders but also in cognitive disorders and conditions associated with fatigue...
  38. ncbi request reprint Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials
    Stephen M Stahl
    Neuroscience Education Institute and Department of Psychiatry, University of California, San Diego, California, USA
    J Clin Psychopharmacol 22:388-92. 2002
    ..The incidence of treatment-emergent agitation or anxiety was comparable between treatment groups...
  39. ncbi request reprint Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder
    Stephen M Stahl
    Neuroscience Education Institute, Carlsbad, CA 92009, USA
    J Clin Psychiatry 64:6-17. 2003
    ..With this approach, the frequently residual symptoms of sleepiness, fatigue, and executive dysfunction can be targeted with bupropion, atomoxetine, modafinil, atypical antipsychotics, and stimulants...
  40. ncbi request reprint Antipsychotic polypharmacy: squandering precious resources?
    Stephen M Stahl
    Neuroscience Education Institute, Carlsbad, Calif 92009, USA
    J Clin Psychiatry 63:93-4. 2002
  41. ncbi request reprint Human sleep EEG following the 5-HT1A antagonist pindolol: possible disinhibition of raphe neuron activity
    E Seifritz
    Mental Health Clinical Research Center, Department of Psychiatry, University of California at San Diego, USA
    Brain Res 759:84-91. 1997
    ....
  42. ncbi request reprint Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?
    P F Buckley
    Department of Psychiatry, Medical College of Georgia, 1515 Pope Avenue, Augusta, GA 30912, USA
    Acta Psychiatr Scand 115:93-100. 2007
    ..Initial enthusiasm that second-generation antipsychotics would prove to be powerful agents to improve negative symptoms has given way to relative pessimism that the effects of current pharmacological treatments are at best modest...
  43. ncbi request reprint Tailoring treatment of depression for women across the reproductive lifecycle: the importance of pregnancy, vasomotor symptoms, and other estrogen-related events in psychopharmacology
    Dana D Wise
    Arbor Scientia, Carlsbad, CA, USA
    CNS Spectr 13:647-62. 2008
    ..To attain optimal outcomes, modern psychopharmacologists must tailor treatment of depression to a woman's reproductive stage of life...
  44. ncbi request reprint Antidepressants and somatic symptoms: therapeutic actions are expanding beyond affective spectrum disorders to functional somatic syndromes
    Stephen M Stahl
    Neuroscience Education Institute in Carlsbad, CA 92009, USA
    J Clin Psychiatry 64:745-6. 2003
    ....
  45. ncbi request reprint Do dopamine partial agonists have partial efficacy as antipsychotics?
    Stephen M Stahl
    Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
    CNS Spectr 13:279-82. 2008
  46. ncbi request reprint Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community
    Stephen M Stahl
    Department of Psychiatry, University of California at San Diego and Neuroscience Education Institute, USA
    J Clin Psychiatry 64:466-72. 2003
    ..We examined the relationship between co-use of donepezil and hypnotics in a large sample of persons with AD living in the community...
  47. ncbi request reprint Effectiveness of St John's wort in major depression: a randomized controlled trial
    R C Shelton
    Department of Psychiatry, Vanderbilt University, Nashville Tennessee, USA
    JAMA 285:1978-86. 2001
    ..Extracts of St John's wort are widely used to treat depression. Although more than 2 dozen clinical trials have been conducted with St John's wort, most have significant flaws in design and do not enable meaningful interpretation...
  48. ncbi request reprint Neurotransmission of cognition, part 1, Dopamine is a hitchhiker in frontal cortex: norepinephrine transporters regulate dopamine
    Stephen M Stahl
    Neuroscience Education Institute, Carlsbad, California 92009, USA
    J Clin Psychiatry 64:4-5. 2003
    ..ISSUE: Since the frontal cortex has a low density of dopamine transporters, dopamine has to be inactivated there by hitching a ride on the norepinephrine transporter of neighboring norepinephrine neurons...
  49. ncbi request reprint Deconstructing psychiatric disorders, Part 1. Genotypes, symptom phenotypes, and endophenotypes
    Stephen M Stahl
    Neuroscience Education Institute, 5857 Owens Street, Ste 102, Carlsbad, CA 92009, USA
    J Clin Psychiatry 64:982-3. 2003
  50. ncbi request reprint At long last, long-lasting psychiatric medications: an overview of controlled-release technologies
    Stephen M Stahl
    Neuroscience Education Institute, Carlsbad, CA 92009, USA
    J Clin Psychiatry 64:355-6. 2003
  51. ncbi request reprint The potential role of a corticotropin-releasing factor receptor-1 antagonist in psychiatric disorders
    Stephen M Stahl
    Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
    CNS Spectr 13:467-83. 2008
  52. ncbi request reprint Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia
    Stephen M Stahl
    Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
    CNS Spectr 12:265-8. 2007
  53. ncbi request reprint Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants
    Stephen M Stahl
    Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
    CNS Spectr 13:855-70. 2008
    ..Those with no previous interest in MAOIs may discover in this article a new "secret weapon" to add to their therapeutic armamentarium for patients who fail to respond to the better-known agents...
  54. ncbi request reprint Independent actions on fear circuits may lead to therapeutic synergy for anxiety when combining serotonergic and GABAergic agents
    Stephen M Stahl
    Neuroscience Education Institute, Carlsbad, CA 92009, USA
    J Clin Psychiatry 63:854-5. 2002
    ..Issue: Both serotonin and GABA powerfully regulate the neuroanatomical circuit that mediates fear in anxiety disorders. This suggests that use of pharmacotherapies acting on both systems may provide synergistic therapeutic actions...
  55. ncbi request reprint Symptoms and circuits, part 1: major depressive disorder
    Stephen M Stahl
    Neuroscience Education Institute in Carlsbad, CA 92009, USA
    J Clin Psychiatry 64:1282-3. 2003
    ..Major depressive disorder comprises multiple symptoms. Each symptom may be mediated by separate and distinct neuronal circuits...
  56. ncbi request reprint Multifunctional drugs: a novel concept for psychopharmacology
    Stephen M Stahl
    Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
    CNS Spectr 14:71-3. 2009
    ..The concept is presented in overview here. Future installments will cover specific drugs in greater depth. Multifunctional drugs include those agents with more than one putative therapeutic mechanism of action...
  57. ncbi request reprint Deconstructing psychiatric disorders, part 2: An emerging, neurobiologically based therapeutic strategy for the modern psychopharmacologist
    Stephen M Stahl
    Neuroscience Education Institute, 5857 Owens Street, Suite 102, Carlsbad, CA 92009, USA
    J Clin Psychiatry 64:1145-6. 2003
  58. ncbi request reprint Mechanism of action of voltage sensitive sodium channel modulators
    Stephen M Stahl
    Neuroscience Education Institute in Carlsbad, CA 92009, USA
    J Clin Psychiatry 65:894-5. 2004
  59. ncbi request reprint Novel therapeutics for schizophrenia: targeting glycine modulation of NMDA glutamate receptors
    Stephen M Stahl
    Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
    CNS Spectr 12:423-7. 2007
  60. ncbi request reprint Norepinephrine and dopamine regulate signals and noise in the prefrontal cortex
    Stephen M Stahl
    Neuroscience Education Institute in Carlsbad, California, and the Department of Psychiatry at the University of California San Diego, CA, USA
    J Clin Psychiatry 70:617-8. 2009
    ..Norepinephrine and dopamine work in a cooperative yet reciprocal manner to regulate information processing at pyramidal neurons in the prefrontal cortex...
  61. ncbi request reprint Psychopharmacology of wakefulness: pathways and neurotransmitters
    Stephen M Stahl
    Neuroscience Education Institute, Carlsbad, Calif 92009, USA
    J Clin Psychiatry 63:551-2. 2002
  62. ncbi request reprint The ups and downs of novel antiemetic drugs, part 1: substance P, 5-HT, and the neuropharmacology of vomiting
    Stephen M Stahl
    Neuroscience Education Institute, Carlsbad, CA 92009, USA
    J Clin Psychiatry 64:498-9. 2003
    ..It is possible that blocking NK(1) receptors elsewhere in the CNS will lead to therapeutic actions in depression and other stress-related disorders...
  63. ncbi request reprint Dosing atypical antipsychotics
    Andrew Cutler
    Department of Psychiatry, University of Florida, Gainesville, FL, USA
    CNS Spectr 13:1-16. 2008
    ....
  64. ncbi request reprint Clinical management of major depressive disorder
    Laurence Mignon
    Neuroscience Education Institute in Carlsbad, CA, USA
    CNS Spectr 14:3-6; quiz 7-8. 2009
    ..Adequately managing residual symptoms will hopefully lead to increased remission in these patients. This supplement focuses on the different types of residual symptoms that patients experience and suggests various treatment options...
  65. ncbi request reprint Personalized medicine, pharmacogenomics, and the practice of psychiatry: on the threshold of predictive therapeutics in psychopharmacology?
    Stephen M Stahl
    Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
    CNS Spectr 13:115-8. 2008
  66. ncbi request reprint Overview of trends in modern psychopharmacology
    Stephen M Stahl
    Neuroscience Education Institute, and Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
    CNS Spectr 12:103-5. 2007
  67. ncbi request reprint Preemptive analgesia: is pain less costly when you pre-pay for it?
    Stephen M Stahl
    Neuroscience Education Institute in Carlsbad, CA 92009, USA
    J Clin Psychiatry 65:1591-2. 2004
    ..ISSUE: Early treatment of pain could thwart the development of chronic persistent painful conditions...
  68. ncbi request reprint Introduction: optimizing wakefulness in patients with fatigue and executive dysfunction
    Stephen M Stahl
    Neuroscience Education Institute, Carlsbad, CA 92009, USA
    J Clin Psychiatry 64:3-4. 2003
  69. ncbi request reprint Antidepressant treatment of psychotic major depression: potential role of the sigma receptor
    Stephen M Stahl
    Neuroscience Education Institute, University of California San Diego, San Diego, CA, USA
    CNS Spectr 10:319-23. 2005
    ....
  70. ncbi request reprint Toward convergence in the medication treatment of bipolar disorder and schizophrenia
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, NY, USA
    Harv Rev Psychiatry 13:28-42. 2005
    ....
  71. ncbi request reprint Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator
    Stephen M Stahl
    Neuroscience Education Institute in Carlsbad, CA 92009, USA
    J Clin Psychiatry 65:1162-3. 2004
    ..Levetiracetam binds selectively and with high affinity to a synaptic vesicle protein known as SV2A, thought to be involved with synaptic vesicle exocytosis and presynaptic neurotransmitter release...
  72. ncbi request reprint Psychopharmacology of anticonvulsants: do all anticonvulsants have the same mechanism of action?
    Stephen M Stahl
    Neuroscience Education Institute, 5857 Owens Street, Suite 102, Carlsbad, CA 92009, USA
    J Clin Psychiatry 65:149-50. 2004
    ..ISSUE: Anticonvulsants are not a single therapeutic class, but are composed of multiple distinct subclasses with different mechanisms of action, efficacies, and side effects...
  73. ncbi request reprint Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines
    Stephen M Stahl
    Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
    CNS Spectr 13:1027-38. 2008
    ..Selective H1 antagonism is emerging as a novel approach to the treatment of insomnia, without tolerance, weight gain, or the need for the restrictive prescription scheduling required of other hypnotics...
  74. ncbi request reprint Mirror, mirror on the wall, which enantiomer is fairest of them all?
    Stephen M Stahl
    Neuroscience Education Institute, 5857 Owens Street, Ste 102, Carlsbad, CA 92009, USA
    J Clin Psychiatry 63:656-7. 2002
    ..Numerous psychotropic drugs exist as a mixture of 2 mirror-image stereoisomers of each other, each called an enantiomer and the mixture called a racemate. Often the drug can be improved when only 1 of the enantiomers is administered...
  75. ncbi request reprint Brainstorms: symptoms and circuits, part 2: anxiety disorders
    Stephen M Stahl
    Neuroscience Education Institute in Carlsbad, Calif 92009, USA
    J Clin Psychiatry 64:1408-9. 2003
    ..Numerous anxiety disorders may have malfunctioning neuronal circuits in common, which may account for the overlapping symptoms and frequent comorbidity of many anxiety disorders with one another...
  76. ncbi request reprint Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders
    Jeanne Stemmelin
    Sanofi Aventis, CNS Research, Bagneux, France
    Neuropsychopharmacology 33:574-87. 2008
    ..Taken as a whole, these findings indicate that the pharmacological stimulation of beta3 adrenoceptors may represent an innovative approach for the treatment of anxiety and depressive disorders...
  77. ncbi request reprint Anticonvulsants as anxiolytics, part 1: tiagabine and other anticonvulsants with actions on GABA
    Stephen M Stahl
    Neuroscience Education Institute, 5857 Owens Street, Carlsbad, CA 92009, USA
    J Clin Psychiatry 65:291-2. 2004
  78. ncbi request reprint The psychopharmacology of energy and fatigue
    Stephen M Stahl
    Neuroscience Education Institute in Carlsbad, Calif 92009, USA
    J Clin Psychiatry 63:7-8. 2002
    ..Recent understanding of interactions between monoaminergic neurons may help explain why some antidepressants may be more rapidly energy restoring than others...
  79. ncbi request reprint Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels
    Stephen M Stahl
    Neuroscience Education Institute in Carlsbad, California 92009, USA
    J Clin Psychiatry 65:596-7. 2004
    ..ISSUE: Anticonvulsants that act as ligands at alpha(2)delta subunits of voltage-gated calcium channels are proving to be novel treatments for chronic pain...
  80. ncbi request reprint Mechanism of action of alpha2delta ligands: voltage sensitive calcium channel (VSCC) modulators
    Stephen M Stahl
    Neuroscience Education Institute in Carlsbad, Calif, and the Department of Psychiatry at the University of California San Diego, 92009, USA
    J Clin Psychiatry 65:1033-4. 2004
    ..Modulation of VSCCs by certain drugs such as pregabalin and gabapentin via binding to the alpha2delta subunits of VSCCs can lead to anticonvulsant, anxiolytic, and chronic pain-relieving actions...
  81. ncbi request reprint The psychopharmacology of painful physical symptoms in depression
    Stephen M Stahl
    Neuroscience Education Institute in Carlsbad, Calif 92009, USA
    J Clin Psychiatry 63:382-3. 2002
  82. ncbi request reprint Anticonvulsants as anxiolytics, part 2: Pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels
    Stephen M Stahl
    Neuroscience Education Institute, 5857 Owens Street, Suite 102, Carlsbad, CA 92009, USA
    J Clin Psychiatry 65:460-1. 2004
  83. ncbi request reprint The effectiveness of St. John's Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication
    Alan J Gelenberg
    University of Arizona Health Sciences Center, Tucson, AZ 85724, USA
    J Clin Psychiatry 65:1114-9. 2004
    ..A continuation study of an extract of St. John's wort (Hypericum perforatum) for depression was performed in follow-up to an acute study that found no significant difference between St. John's wort extract and placebo...
  84. ncbi request reprint Drug combinations for bipolar spectrum disorders: evidence-based prescribing or prescribing-based evidence?
    Stephen M Stahl
    Neuroscience Education Institute in Carlsbad, Calif 92009, USA
    J Clin Psychiatry 65:1298-9. 2004
  85. ncbi request reprint Positive findings for negative symptoms of schizophrenia: no longer untreatable?
    Stephen M Stahl
    Acta Psychiatr Scand 114:301-2. 2006
  86. ncbi request reprint Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder
    Marcia F T Rupnow
    Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, NJ 08560, USA
    Curr Med Res Opin 23:2815-22. 2007
    ..The use of adjunctive psychotropics and the costs of polypharmacy in patients randomized to receive risperidone or quetiapine were compared in a placebo-controlled double-blind study conducted in India, Romania, and the United States...
  87. ncbi request reprint Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder
    Stephen M Stahl
    J Clin Psychiatry 63:756-7. 2002
  88. ncbi request reprint The ups and downs of novel antiemetic drugs, part 2: an illustration
    Stephen M Stahl
    Neuroscience Education Institute in Carlsbad, Calif, and the Department of Psychiatry at the University of California San Diego, CA92009, USA
    J Clin Psychiatry 64:626-7. 2003
    ....
  89. ncbi request reprint Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies
    George I Papakostas
    Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 69:1287-92. 2008
    ....
  90. ncbi request reprint Prophylactic antipsychotics: do they keep you from catching schizophrenia?
    Stephen M Stahl
    Neuroscience Education Institute in Carlsbad, Calif 92009, USA
    J Clin Psychiatry 65:1445-6. 2004
  91. ncbi request reprint A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder
    Eric Hollander
    Department, of Psychiatry, Box 1230, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, USA
    World J Biol Psychiatry 4:30-4. 2003
    ..Its effectiveness in specific subgroups of OCD patients with co-morbid anxiety disorders or as an augmentation strategy added to SSRIs remains to be determined...
  92. ncbi request reprint Is psychopharmacologic "inoculation" effective in preventing posttraumatic stress disorder?
    Stephen M Stahl
    Neuroscience Education Institute in Carlsbad, CA 92099, USA
    J Clin Psychiatry 66:5-6. 2005
  93. ncbi request reprint Can psychopharmacologic treatments that relieve symptoms also prevent disease progression?
    Stephen M Stahl
    Neuroscience Education Institute in Carlsbad, Calif, USA
    J Clin Psychiatry 63:961-2. 2002